Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2015

01-01-2015 | Editorial

Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?

Authors: Mohammed Eslam, Jacob George

Published in: Hepatology International | Issue 1/2015

Login to get access

Excerpt

Hepatitis C virus (HCV) infects ~3 % of the world population and an estimated 3–4 million new infections occur each year [1]. Not only is the virus a leading cause of chronic liver disease, but it is also associated with extrahepatic complications including type 2 diabetes and cardiovascular disease [2, 3]. …
Literature
1.
2.
3.
Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477PubMedCrossRef
4.
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology. 2014;59:318–327PubMedCentralPubMedCrossRef
5.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014
6.
Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–759PubMedCrossRef
7.
Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50(6):1142–1154PubMedCrossRef
8.
Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–120PubMedCentralPubMedCrossRef
9.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982PubMedCrossRef
10.
Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364PubMedCrossRef
11.
Andriulli A, Morisco F, Ippolito AM, Di Marco V, Valvano MR, Angelico M, et al. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int. 2014;1–6
12.
Ottenbacher KJ, Maas F. How to detect effects: statistical power and evidence-based practice in occupational therapy research. Am J Occup Ther. 1999;53:181–188PubMedCrossRef
13.
Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol. 2014;61(2):235–241PubMedCrossRef
14.
Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011;53:1090–1099PubMedCrossRef
15.
Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59(6):2403–2412PubMedCrossRef
16.
Gilead Sciences. Sovaldi Full Prescribing Information, Valence Data. Foster City, CA: Gilead Sciences 2013
17.
Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138(2):447–462PubMedCrossRef
18.
Howe A, Long J, Thompson S, Barnard R, Alves K, Howe J, et al. Interim analysis of the durability of response and persistence of resistance associated variants during long term follow after boceprevir + pegylated interferon/ribavirin. Hepatology 2013; p. 1849 (Abstract)
19.
Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naïve patients prior to treatment. J Virol. 2013;87:1544–1553PubMedCentralPubMedCrossRef
20.
Tran TT, Morgan TR, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, et al. Safety and efficacy of treatment with sofosbuvir + GS-5816 ± ribavirin for 8 or 12 weeks in treatment naïve patients with genotype 1–6 HCV infection. Hepatology. 2014;60(Suppl. 1):237A
21.
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. High efficacy of treatment with sofosbuvir + GS-5816 ± ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. Hepatology. 2014;60(Suppl. 1):297A–298A
Metadata
Title
Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
Authors
Mohammed Eslam
Jacob George
Publication date
01-01-2015
Publisher
Springer India
Published in
Hepatology International / Issue 1/2015
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-014-9600-2

Other articles of this Issue 1/2015

Hepatology International 1/2015 Go to the issue

Original Article

Reimbursement policies in the Asia-Pacific for chronic hepatitis B

Editorial

Use of BAR score as predictor of short and long-term survival of liver transplantation patients

Original Article

Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC

Original Article

A comparative study of patients’ knowledge about hepatitis C in the United States and in urban and rural China

Original Article

Insulin-like growth factor binding protein-related protein 1 (IGFBPrP1) contributes to liver inflammation and fibrosis via activation of the ERK1/2 pathway

Review Article

How to achieve immune control in chronic hepatitis B?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits